▲ 2.35%
prev close
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-02-16 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1327d ago | — | |
| 2022-11-01 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1414d ago | — |
2023-02-16
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1327d ago
2022-11-01
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1414d ago
Recent News
Powered by Polygon.io
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment
Trade Timeline
Congressional activity, newest first
Virginia Foxx
2023-02-16 · Purchase
$1,001 - $15,000
Virginia Foxx
2022-11-01 · Purchase
$1,001 - $15,000